We showed that our AI technology can quickly sift through massive amounts of data to find the most consequential evidence. We then deployed our technology to rigorously analyze 16,000 published studies and identify the most promising non-cancer generic drugs for the treatment of prostate cancer.

We received a $1.5 million donation, which enabled us to launch Reboot Rx and hit the ground running in 2020 towards our goal of saving the lives of cancer patients with existing non-cancer generic drugs. We built our evidence synthesis pipeline and a working prototype of our AI technology that efficiently prioritizes drug repurposing candidates at scale, and we completed a proof of concept of our technology.